Stroke Treatment and Prevention: From Clinical Trials to Daily Practice

51st Meeting of the Spanish Society of Neurology, Barcelona, December 16, 1998

Guest Editor
A. Chamorro, Barcelona

6 figures and 17 tables, 1999
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Contents

Acute Treatment

1 Deteriorating Stroke: Diagnostic Criteria, Predictors, Mechanisms and Treatment
Castillo, J. (Santiago de Compostela)

9 Fibrinolytic Therapy for Acute Stroke: The Spanish Experience
Dávalos, A. (Girona) on behalf of the ECASS-II Spanish Group

16 Heparin in Acute Ischemic Stroke: The Case for a New Clinical Trial
Chamorro, A. (Barcelona)

Secondary Stroke Prevention

24 Secondary Stroke Prevention with Drugs: Single or Combined Therapy?
van Gijn, J.; Algra, A. (Utrecht)

29 Secondary Stroke Prevention: A European Perspective
Devuyst, G.; Paciaroni, M.; Bogousslavsky, J. (Lausanne)

Sacco, R.L. (New York, N.Y.)

Thomas Willis Lecture

45 Acute Clinical Trials: An Expression of Concern
Mohr, J.P. (New York, N.Y.)